{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:37:59Z","timestamp":1784957879045,"version":"3.55.0"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Albumin has been shown to be safe and effective in clinical practice for a wide variety of indications. The purpose of this medication use evaluation is to quantify the use of albumin in the community hospital setting based on indication and prescribing department.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study is a retrospective, single-center, chart review over a 6-month period of 186 patients aged 18 and older who were treated with IV human albumin 5% or 25% at a single 202-bed community hospital setting from February 1, 2020, to August 1, 2020. A chart review was completed for each patient and the data collected included date of albumin administration, the ordering provider, the specialty of the provider, the indication for albumin as stated in the order, patient notes, crystalloid therapy use prior to albumin, albumin strength, the presence of acute or chronic renal, hepatic or respiratory disorders, and lab values denoting renal and hepatic function. Appropriate albumin use was determined utilizing criteria which included FDA labeled indications, the Surviving Sepsis Campaign, and existing literature.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 186 patients received albumin 5% or 25% IV solution at least once during the study period. The study population was 52.2% female, and the average age was 68 years. Of the patients selected for the study, 23 (11.6%) had chronic hepatic disease, and 37 (18.7%) had chronic renal disease. The top indications for which albumin was administered were sepsis or septic shock (25.3%), hypotension or hypovolemia (19.4%), intra-dialytic hypotension (13.4%), fluid support in surgery (10.8%), and nephrosis or nephropathy (10.8%). The departments with highest albumin use during this study period were critical care (41%), nephrology (28%), and surgery (17%). Overall, albumin was used for an appropriate indication in 126 out of 186 patients (67.7%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We found that albumin was most utilized for sepsis and septic shock, hypovolemia and hypotension, and intradialytic hypotension in our community hospital setting and it was most frequently ordered by critical care, nephrology, and surgical departments. Further research could determine if this trend is seen in other community hospital settings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0257858","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T21:28:52Z","timestamp":1633555732000},"page":"e0257858","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of albumin use in a community hospital setting: A retrospective study looking at appropriate use and prescribing patterns"],"prefix":"10.1371","volume":"16","author":[{"given":"Timothy","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-2450","authenticated-orcid":true,"given":"Samuel M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"pone.0257858.ref001","unstructured":"Albumin (Human) [package insert]. Paramus, NJ: Octapharma; 2006."},{"issue":"4","key":"pone.0257858.ref002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc13991","article-title":"Albumin administration in the acutely ill: what is new and where next?","volume":"18","author":"JL Vincent","year":"2014","journal-title":"Crit Care"},{"issue":"22","key":"pone.0257858.ref003","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","article-title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","volume":"350","author":"S Finfer","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"pone.0257858.ref004","first-page":"s18","article-title":"Clinical use of albumin","volume":"11","author":"P Caraceni","year":"2013","journal-title":"Blood Transfus"},{"key":"pone.0257858.ref005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jcrc.2016.04.019","article-title":"Fluid management in sepsis: The potential beneficial effects of albumin","volume":"35","author":"JL Vincent","year":"2016","journal-title":"J Crit Care"},{"issue":"3","key":"pone.0257858.ref006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: InternationalGuidelines for Management of Sepsis and Septic Shock: 2016","volume":"43","author":"A Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"issue":"2","key":"pone.0257858.ref007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/CCM.0b013e3181ffe217","article-title":"The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis","volume":"39","author":"AP Delaney","year":"2011","journal-title":"Crit Care Med"},{"issue":"10","key":"pone.0257858.ref008","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archsurg.143.10.935","article-title":"Albumin use guidelines and outcome in a surgical intensive care unit","volume":"143","author":"A Charles","year":"2008","journal-title":"Arch Surg"},{"issue":"2","key":"pone.0257858.ref009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1060028019877471","article-title":"Clinical Pharmacist-Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill","volume":"54","author":"MS Buckley","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"15","key":"pone.0257858.ref010","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa1305727","article-title":"Albumin replacement in patients with severe sepsis or septic shock","volume":"370","author":"P Caironi","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0257858.ref011","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s13054-014-0702-y","article-title":"Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials","volume":"18","author":"JY Xu","year":"2014","journal-title":"Crit Care"},{"issue":"5","key":"pone.0257858.ref012","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.09670620","article-title":"Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy","volume":"16","author":"N Hryciw","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0257858.ref013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1523-1755.1999.00298.x","article-title":"Coadministration of albumin and furosemide in patients with the nephrotic syndrome","volume":"55","author":"D Fliser","year":"1999","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0257858.ref014","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.18549\/PharmPract.2018.02.1190","article-title":"Assessing adherence to current national guidelines for appropriate albumin use at an academic medical center","volume":"16","author":"AM Castillo","year":"2018","journal-title":"Pharm Pract (Granada)"},{"issue":"11","key":"pone.0257858.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2019.08.023","article-title":"A Cost-effectiveness Analysis of Albumin in Septic Shock: A Patient-level Data Analysis","volume":"41","author":"BM Tigabu","year":"2019","journal-title":"Clin Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T21:29:17Z","timestamp":1633555757000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257858"}},"subtitle":[],"editor":[{"given":"Aleksandar R.","family":"Zivkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257858","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]}}}